Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: Galecto acquires Damora Therapeutics
Lucid Diligence Brief: Galecto acquires Damora Therapeutics Professional…
Lucid Diligence Brief: Electra Therapeutics $183M Series C
Lucid Diligence Brief: Electra Therapeutics $183M Series C Professional…
Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025)
This week’s hematology update highlights groundbreaking CAR-T and gene therapy…
Women's Health Weekly News - August 20th 2025
Women’s Health Breakthroughs: Migraine, Fibromyalgia, Postpartum Depression and…
Rare Diseases Weekly News - August 14th 2025
🧬 This Week in Rare Diseases: FDA Approvals, Global Partnerships, Breakthrough…
Rare Diseases Weekly News - July 31st 2025
🧬 This Week in Rare Diseases: FDA Leadership, Gene Therapy Safety, New Drug…
EHA 2025 Preview: Key Hematology Highlights to Watch
EHA at a glance Join LucidQuest for a concise EHA 2025 preview, focusing on…
Cell and Gene Therapy Weekly News - May 29th 2025
This Week in Gene & Cell Therapy: Clinical Trial Expansions, Rare Disease…
How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…
How we helped two pharma companies assess their own and their competitors' social media during ESMO 2023 and ASCO 2023.
The Challenge: How to maximize the benefits of social media monitoring during…